A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales.

Colin BurkeCatriona CrossanEmma Tyas Matthew Hemstock Dawn Lee Sally Bowditch

Published in: PharmacoEconomics - open (2024)

At 12 mg/kg/day and an ICER threshold of £20,000-£30,000, we provide evidence for the cost effectiveness of add-on cannabidiol treatment for patients with TSC-associated seizures aged ≥ 2 years who are refractory to current treatment.

Keyphrases

replacement therapy